• Daily Marijuana Observer Facebook
  • Daily Marijuana Observer Twitter
  • Daily Marijuana Observer StockTwits
  • Daily Marijuana Observer SA
  • Daily Marijuana Observer Instagram
  • Daily Marijuana Observer Youtube
  • Pinterest Social Icon
  • Daily Marijuana Observer Talk Market

THC and Migraines: Study Indicates Tetrahydrocannabinol Can Help

November 24, 2017

 

A recent study published in the European Journal of Pharmacology examined the use of cannabinoids as a treatment for migraines in female rats and found THC has the power to reduce migraine-like pain.

 

Migraine headaches adversely affect more than 4 million Americans daily. Considered the sixth most disabling illness in the world, migraines that can last for 72 hours plague 12 percent of the U.S. population, according to the Migraine Research Foundation.

 

But thanks in part to funding from the passage of I-502 in 2012 and motivation from a survey indicating 10.2 percent of those suffering from migraine headaches in Germany, Austria, and Switzerland self-medicate with marijuana, researchers at Washington State University (WSU) were given the opportunity to examine the possible correlation between marijuana and migraines.

 

For the study, Dr. Ram Kandasamy of WSU’s Department of Integrative Physiology and Neuroscience examined the medical efficacy of the most famous cannabinoid by administering a precise dose of ∆9-tetrahydrocannabinol (THC) to female rats, at specific times.

 

The study notes that female rats were selected because a “migraine is much more common in women than men (Vetvik and MacGregor, 2016).”

 

“The present study tested whether administration of ∆9-tetrahydrocannabinol (THC) produces anti-migraine effects in the female rat. Microinjection of the TRPA1 agonist allyl isothiocyanate (AITC) onto the dura mater produced migraine-like pain for 3 h as measured by depression of home cage wheel running. Concurrent systemic administration of 0.32 but not 0.1 mg/kg of THC prevented AITC-induced depression of wheel running. However, 0.32 mg/kg was ineffective when administered 90 min after AITC.”

 

Note: Scientists viewed the home cage wheel activity as particularly useful in determining each rat’s stress level, and according to the scientists, only stress-free rats run for extended periods of time.

 

After anesthetizing and studying “48 adult female Sprague-Dawley rats,” researchers discovered a “higher dose of THC (1.0 mg/kg) depressed wheel running whether rats were injected with AITC or not. Administration of a CB1, but not a CB2, receptor antagonist attenuated the anti-migraine effect of THC.”

 

The results infer two intriguing points

  • THC reduces migraine-like pain when administered at the right dose – 0.32 mg/kg – and time.

  • THC’s anti-migraine effect is mediated by the brain’s CB1 receptors.

     

While this migraine study was conducted within the restrictive guidelines of our federally enforced Controlled Substance Act, Marijuana.com reported on an Italian study published in June that utilized 127 human subjects. During that two-phase study, 43.5 percent of participants reported a noteworthy decline in their overall migraine-related discomfort levels, thanks to the use of cannabinoids.

 

This article was originally published on Marijuana.com

 

About Monterey Bud: Born in Long Beach, raised on the central coast: I surf, dab, burn, and blog – though not necessarily in that order. I'm a husband, a father and a lifelong consumer of connoisseur grade weed. I don't drink alcohol or consume any other "drugs." I consider myself to be living proof that weed is not a gateway drug. If it were, I'd be in some serious trouble. Instead, as a 50-year-old ex-realtor that has been smoking weed for nearly 80% of my life (just did the math) ... I can only say, marijuana is safer than prescription pills or alcohol could ever hope to be for calming what stirs the savage beast.

Please reload

LATEST NEWS
Please reload

Please reload

DMO

© Copyright 2016-2020 Smoke Show Ventures, Inc.

RSS Feed

Disclaimer: Except for the historical information and data presented herein, matters discussed in articles on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future performance or achievements expressed or implied by such coverage. Smoke Show Ventures, Inc., which owns The Daily Marijuana Observer, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Smoke Show Ventures, Inc., which owns The Daily Marijuana Observer, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. Before making specific investment decisions, readers should seek their own professional advice and that of their own professional financial adviser. Smoke Show Ventures, Inc. or its affiliates, which owns The Daily Marijuana Observer, may be compensated for its services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.dailymarijuanaobserver.com/legal-disclaimer/.